MedTrace Logo

A Study of TG103 Injection in Type 2 Diabetes Subjects

NCT05348122 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2022-06-13

No results posted yet for this study

Summary

The primary objective of this trial is to evaluate the efficacy of different doses and frequencies of administration of TG103 injection in the treatment of type 2 diabetes.

Conditions

Interventions

DRUG

TG103,Q2W

TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.

DRUG

TG103,QW

TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

DRUG

Placebo,Q2W

Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.

DRUG

Placebo,QW

Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

DRUG

Dulaglutide,QW

Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

Sponsors & Collaborators

  • CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Linong Ji · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2023-11-01
Completion
2023-11-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05348122 on ClinicalTrials.gov